<DOC>
	<DOC>NCT00868660</DOC>
	<brief_summary>Healthy Normal Single Ascending Dose and Crohn's patient Multiple Ascending Dose</brief_summary>
	<brief_title>Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose</brief_title>
	<detailed_description>A Phase I, Double blind, Placebo-controlled, safety and tolerability study of ZP1848 administered as Ascending single Dose, SUBCUTANEOUS bolus injections in healthy SUBJECTS followed by a Multiple Dose cohort of patients with stable Crohn's disease in remission</detailed_description>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Healthy adult male and/or females, 18 to 50 years of age Body mass index (BMI)1830. Chrons Inclusion Adult male and/or females, 18 to 60 years of age (inclusive). Body mass index (BMI) ≥ 18 and ≤ 30 (kg/m2). Crohn's Disease Activity Index (CDAI) score &lt; 150. In a stable state of Crohn's disease as per the Investigator's opinion. Free of steroid treatment (therapy targeted for the GI tract only) within the 3 months prior to Day 1. History or presence of dysplasia, cancer, chronic hepatitis, HIV, tuberculosis (TB), or histoplasmosis. Fistula within the 3 months prior to dosing. 3. Ostomy (having ostomy now or at any time in the past). 4. Any surgery for the treatment of inflammatory bowel disease (IBD) within the 3 months prior to Day 1. 5. Short Bowel Syndrome (SBS). 6. Any other condition, chronic disease, or prior therapy, which in the opinion of the Investigator/Investigator's designee would put the patient at undue risk or would make the patient unsuitable for the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>